BioSpace News Archive

Quotient Limited, a commercial-stage diagnostics company, announced that the Company will present at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 1:20pm ET.

OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Raymond James 42nd Annual Institutional Investors Conference.

10x Genomics, Inc. detailed a slew of new products and announced the acquisition of Copenhagen-based Tetramer Shop at its inaugural Xperience 2021 event, a showcase with three breakout sessions corresponding to 10x’s three product platforms: Chromium Single Cell, Visium Spatial, and In Situ Analysis.

BridgeBio Pharma, Inc. announced that early results from an ongoing Phase 2 proof-of-concept study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 will be shared at the upcoming Endocrine Society’s 2021 Annual Meeting taking place virtually from March 20 - 23.

Further established leadership in sickle cell disease (SCD) with data presentations on pipeline programs inclacumab and GBT021601 (GBT601)

-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021 -- Paratek Expects Full Year 2021 Total Revenue Between $166 and $177 Million

Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced a 10-year CEO performance stock award for David Fischel with vesting entirely contingent upon the company achieving billion-dollar market capitalization milestones.

Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI® Product Revenue

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full-year ended December 31, 2020.

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2020.